DIA
30.1.2024 10:01:28 CET | Business Wire | Press release
DIA, a global organization of life sciences professionals, will emphasize how collaboration and innovation can support sustainability in healthcare at DIA Europe 2024, to be held March 12-14 at Square Brussels Convention Centre in Brussels.
DIA Europe, the largest and most forward-looking neutral healthcare conference on the continent, is the only event that gives representatives from the European Commission, the European Medicines Agency (EMA), the World Health Organization (WHO), the Heads of Medicines Agencies (HMA), national competent authorities, healthcare professionals, and patient populations the opportunity to come together to shape key policy decisions.
Now in its 36th year, DIA Europe will feature discussions on the environmental footprint of pharmaceuticals and drug development. Panelists will explore optimal sustainability practices with more than 250 guest speakers across 11 rich content tracks that comprise 100-plus sessions, including much-anticipated "DIAmond sessions" and town halls. They will also participate in collaboration hubs, showcases, and workshops designed to drive change and innovative thinking.
"Sustainability is one of the defining challenges in healthcare today," said Ania Mitan, DIA's Senior Vice President and Managing Director, EMEA and India. "No organization can tackle it alone, but through open dialogue, partnership across industry, government, and academia, and listening to the patient's perspective, we can drive real progress. Learning from each other will empower us to develop new approaches that benefit patients, society, and our planet."
Attendees will hear from more than 25 EMA executives, including Emer Cooke, the Executive Director of the EMA and the Chair of the International Coalition of Medicines Regulatory Authorities (ICMRA); Martin Harvey Allchurch, the EMA's Head of International Affairs; and Dr. Peter Arlett, the EMA's Head of Data Analytics and Methods Task Force.
Leda Stott, a Senior Research Fellow at the Innovation and Technology for Development Centre at the Technical University of Madrid and an authority on multi-stakeholder collaboration; Veronique Toully, the Global Head of Sustainability, Corporate Affairs and Risks at UCB; and Dr. Glenn Wells, Chief Partnerships Officer at the Medicines and Healthcare Products Regulatory Agency (MHRA), will deliver a keynote address that examines healthcare's most pressing sustainability challenges.
Other can't-miss sessions include:
— "EU Regulatory Town Hall: The New Pharmaceutical Legislation": Explore how we are increasing availability and access to novel healthcare solutions.
— "Digital Transformation in the EU Regulatory Space": Discuss how Europe is building the foundations for its digital transformation in the regulatory space for the next 10 years.
— "Complexity: Interplay and Interface of Different Legislations": Learn how we can drive medicine research, development, and manufacturing amid an increasingly complicated landscape of EU policies and regulations.
Three new content tracks this year will cover emerging trends in healthcare: Artificial Intelligence, Data Science, and Real-World Evidence; Innovative Therapies, Precision Medicine, and Diagnostics; and International Collaboration and Regional Updates.
DIA is celebrating 60 years of bringing together leading minds to foster innovation, collaboration, and advancement in global healthcare.
At DIA Europe, everyone meets on equal terms. To register to attend as a participant or media member, visit https://www.diaglobal.org/Flagship/DIA-Europe-2024.
About DIA
DIA is a leading global life science membership association that drives collaboration in drug, device, and diagnostics development in pursuit of a healthier world. Founded in 1964 with headquarters in Washington, D.C., and offices in Europe and Asia, DIA provides unparalleled networking opportunities, educational resources, scientific research publications, and professional development programs to members in more than 80 countries.
Learn more at DIAglobal.org, and connect with DIA on LinkedIn, Facebook, X (Twitter), and Instagram.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240130133798/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting udvider sin teknologiplatform i Frankrig20.3.2026 17:28:00 CET | Pressemeddelelse
Andersen Consulting udvider sit udbud inden for digital transformation med en samarbejdsaftale med Teolia Consulting, et fransk firma, der specialiserer sig i projekt- og produktstyring, cloud-platformsudvikling, datatransformation samt implementering og brug af Atlassian-pakken. Teolia Consulting blev grundlagt i 2014 og hjælper organisationer med at opnå digital performance, fra agile metoder til løsninger, der reducerer lanceringstiden. Virksomhedens ekspertise består i at levere integrerede strategier, der bringer teknologi og organisatorisk forandring i overensstemmelse. Virksomheden arbejder på tværs af brancher, herunder inden for bank- og finanssektoren, forsikring, mode og detailhandel, og hjælper kunder med at få større robusthed og accelerere deres digitale modenhed. "Hos Teolia Consulting mener vi, at ægte transformation opstår, når teknologi og mennesker udvikler sig sammen," sagde Lucienne Jacquet, der er administrerende partner i Teolia. "Ved at samarbejde med Andersen C
Incyte to Highlight Late-Breaking Hidradenitis Suppurativa Data at the 2026 American Academy of Dermatology (AAD) Annual Meeting20.3.2026 15:00:00 CET | Press release
- New, late-breaking 54-week data for povorcitinib in hidradenitis suppurativa (STOP-HS1 & STOP-HS2) to be highlighted - Featured abstracts for ruxolitinib cream (Opzelura®) and povorcitinib include multiple ePosters in atopic dermatitis, hidradenitis suppurativa and vitiligo Incyte (Nasdaq:INCY) today announced that data from key programs in its Inflammation and Autoimmunity (IAI) franchise will be presented at the 2026 American Academy of Dermatology (AAD) Annual Meeting, to be held March 27 – 31, 2026, in Denver. “At AAD 2026, we are presenting late‑breaking 54-week results from the Phase 3 STOP‑HS program evaluating povorcitinib in hidradenitis suppurativa (HS),” said Jim Lee, M.D., Ph.D., Group Vice President, Inflammation and Autoimmunity, Incyte. “These data provide longer term evidence of the safety and efficacy of povorcitinib in HS patients and further strengthen the significant growth potential of our Inflammation and Autoimmunity franchise.” Details on key data presentation
MUSASHI JAPAN by TAIMATSU Launches “Road to Shogun” – A Journey Through Craftsmanship and Discovery20.3.2026 13:58:00 CET | Press release
Musashi Japan by TAIMATSU Co., Ltd., a contemporary Japanese knife brand rooted in the spirit of craftsmanship and cultural harmony, has announced its newest experiential campaign: “Road to Shogun.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260320887471/en/ Designed as the brand’s most ambitious customer journey to date, the campaign invites visitors to explore participating Musashi Japan stores while discovering the traditions, culture and craftsmanship that inspire the brand. Inspired by the journey towards mastery, the experience encourages participants to progress through a series of ranks whilst visiting stores and unlocking rewards that celebrate elements of everyday Japanese culture. At Musashi Japan, craftsmanship is not only about the final product, but also about the path taken to achieve mastery. The Road to Shogun reflects this philosophy by guiding customers through a journey that mirrors the dedication, cu
Futur Delivers Strong Growth and Record Profit in 202520.3.2026 12:05:00 CET | Press release
In 2025, Futur added 21,000 new customers and the inflows amounted to 34 billion kronor. At the end of the year, the total savings capital was 252 billion kronor, an increase of 7% from the previous year and a new record level. "2025 was a record year for Futur. In a market characterized by sharp market fluctuations, Futur continued to invest, grow and deliver strong results. Behind this record performance is stable customer growth, strong inflows and cost discipline. Our close cooperation with over 60 partners gives customers the freedom to choose the asset management and advisory services that best suit them. The strategy of letting the customer choose is appreciated, which is reflected in us welcoming more than 21,000 new customers during the year", says Torgny Johansson, CEO of Futur. "We are optimistic about the future. Futur has great opportunities to continue growing in the coming years by developing innovative and efficient services for savings and pensions. I am proud of how a
Lyten to Establish a Lyten Industrial Hub in Poland20.3.2026 12:00:00 CET | Press release
Lyten announces the establishment of its next Lyten Industrial Hub in Gdańsk, Poland. The hub will bring together key manufacturing and digital resources to support energy infrastructure, the development of artificial intelligence, and the defense sector. In February 2026, Lyten announced the creation of the first Lyten Industrial Hub in Sweden, combining battery production operations there with a 1 GW AI data center campus. Lyten plans to complete its feasibility study by the end of 2026 to determine the full development plan Lyten, the supermaterial applications company and global leader in an energy storage, has announced its interest in establishing a Lyten Industrial Hub in Poland. In 2026, Lyten will conduct a feasibility study to assess manufacturing requirements for Lyten products, potential private and public partnerships, and the necessary energy and utility infrastructure. The industrial hub will be built around Lyten Dwa – the energy storage production plant and R&D center
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
